...
首页> 外文期刊>Precision Clinical Medicine >Evidence-based medicine and precision medicine: Complementary approaches to clinical decision-making
【24h】

Evidence-based medicine and precision medicine: Complementary approaches to clinical decision-making

机译:循证医学和精密医学:临床决策的补充方法

获取原文
           

摘要

Evidence-based medicine is widely promoted for decision-making in health care and is associated with improved patient outcomes. Critics have suggested that evidence-based medicine focuses primarily on groups of patients rather than individuals, but often fail to consider subgroup analyses, N-of-1 trials, and the incorporation of patient values and preferences. Precision medicine has been promoted as an approach to individualize diagnosis and treatment of diseases through genetic, biomarker, phenotypic, and psychosocial characteristics. However, there are often high costs associated with personalized medicine, and high-quality evidence is lacking for effectiveness in many applications. For the potential of personalized medicine to be realized, it must adhere to the principles of evidence-based medicine: (1) evidence in isolation is not sufficient to make clinical decisions—patient’s values and preferences as well as resource implications must be considered, and (2) there is a hierarchy of evidence to guide clinical decision-making and studies at lower risk of bias are likely to provide more trustworthy findings.
机译:循证医学在医疗保健决策中得到广泛推广,并与改善患者预后相关。批评者认为,循证医学主要关注患者群体,而不是个人,但是常常不能考虑亚组分析,N-of-1试验以及患者价值和偏好的纳入。精密医学已被推广为通过遗传,生物标记,表型和社会心理特征来个性化诊断和治疗疾病的方法。但是,与个性化医疗相关的费用通常很高,并且在许多应用中缺乏有效的高质量证据。为了实现个性化医学的潜力,它必须遵守循证医学的原则:(1)孤立的证据不足以做出临床决策-必须考虑患者的价值观和偏好以及对资源的影响,以及(2)有分层的证据指导临床决策,而偏倚风险较低的研究则可能会提供更多值得信赖的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号